A new breakthrough drug to treat the most common form of cystic fibrosis in patients has officially been approved by the U.S. Food and Drug Administration, Forbes reported.
Trikafta is the first triple combination therapy available to treat CF patients and has already been dubbed a 'miracle' treatment by one of its trial users.